{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:12:49Z","timestamp":1793236369687,"version":"4.5.0"},"reference-count":52,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Radioactive iodine has been considered a safe and effective therapeutic option for hyperthyroidism secondary to Graves disease and autonomously functioning thyroid nodules since the mid-20th century. The question of whether I-131 at the doses used for hyperthyroidism might increase the risk of cancer has been investigated in a number of observational cohort studies over the years, with the preponderance of evidence being reassuring as to its safety. In particular, the 1998 Cooperative Thyrotoxicosis Therapy Follow-up Study (CTTFUS) has been widely cited as compelling evidence that I-131 is safe in hyperthyroidism therapy with respect to carcinogenesis. However, in 2019, a study by Kitahara and colleagues re-analyzed the CTTFUS cohort, extending the follow-up time and applying a novel dosimetric model for estimating tissue absorbed doses of radiation. This new analysis concluded that radioactive iodine was associated with an increased risk for mortality from overall cancer, breast cancer, and non-breast solid cancers. Reaction to this study was vociferous and particularly negative in the nuclear medicine literature. This mini-review was inspired by the 2019 CTTFUS controversy, and it is intended to provide the necessary context for clinicians to provide nuanced advice to their patients on the subject. To that end, the pre-2019 literature is surveyed, the 2019 CTTFUS study and a 2020 follow-up are discussed, and lessons from the literature and critical commentaries are considered.<\/jats:p>","DOI":"10.1210\/clinem\/dgab700","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T17:42:01Z","timestamp":1632418921000},"page":"e448-e457","source":"Crossref","is-referenced-by-count":26,"title":["Does Radioactive Iodine Therapy for Hyperthyroidism Cause Cancer?"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6540-1110","authenticated-orcid":false,"given":"Brian W","family":"Kim","sequence":"first","affiliation":[{"name":"Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"issue":"4","key":"2022011806195922400_CIT0001","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","article-title":"Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group","volume":"280","author":"Ron","year":"1998","journal-title":"JAMA."},{"issue":"5","key":"2022011806195922400_CIT0002","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/MED.0000000000000561","article-title":"Cancer incidence and mortality following treatment of hyperthyroidism with radioactive iodine","volume":"27","author":"Evron","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"12","key":"2022011806195922400_CIT0003","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022011806195922400_CIT0004","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"84","author":"Bartalena","year":"2016","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2022011806195922400_CIT0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2020.0114","article-title":"Shifting trends and informed decision-making in the management of Graves\u2019 disease","volume":"30","author":"Seib","year":"2020","journal-title":"Thyroid."},{"issue":"10","key":"2022011806195922400_CIT0006","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid."},{"key":"2022011806195922400_CIT0007","doi-asserted-by":"crossref","first-page":"m41","DOI":"10.1136\/bmj.m41","article-title":"Thyroid disease assessment and management: summary of NICE guidance","volume":"368","author":"Vasileiou","year":"2020","journal-title":"BMJ."},{"issue":"8","key":"2022011806195922400_CIT0008","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamainternmed.2019.0981","article-title":"Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism","volume":"179","author":"Kitahara","year":"2019","journal-title":"JAMA Intern Med."},{"issue":"5","key":"2022011806195922400_CIT0009","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/ERC-12-0176","article-title":"Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis","volume":"19","author":"Hieu","year":"2012","journal-title":"Endocr Relat Cancer."},{"issue":"24","key":"2022011806195922400_CIT0010","doi-asserted-by":"crossref","first-page":"13761","DOI":"10.1073\/pnas.2235592100","article-title":"Cancer risks attributable to low doses of ionizing radiation: assessing what we really know","volume":"100","author":"Brenner","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2022011806195922400_CIT0011","volume-title":"Committee to Assess Health Risks from Exposure to Low Level of Ionizing Radiation. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2","author":"National Research Council (U.S.)"},{"key":"2022011806195922400_CIT0012","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40336-013-0022-2","article-title":"Is radioiodine treatment for thyroid cancer a risk factor for second primary malignancies?","volume":"1","author":"Dottorini","year":"2013","journal-title":"Clin Transl Imaging."},{"issue":"1","key":"2022011806195922400_CIT0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jrr\/rrx049","article-title":"Persistent in vivo cytogenetic effects of radioiodine therapy: a 21-year follow-up study using multicolor FISH","volume":"59","author":"Livingston","year":"2018","journal-title":"J Radiat Res."},{"issue":"5","key":"2022011806195922400_CIT0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/thy.2008.0392","article-title":"Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis","volume":"19","author":"Sawka","year":"2009","journal-title":"Thyroid."},{"issue":"12","key":"2022011806195922400_CIT0015","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1089\/thy.2018.0244","article-title":"A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer","volume":"28","author":"Yu","year":"2018","journal-title":"Thyroid."},{"issue":"1","key":"2022011806195922400_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid."},{"key":"2022011806195922400_CIT0017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fonc.2013.00073","article-title":"Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk","volume":"3","author":"Braunstein","year":"2013","journal-title":"Front Oncol."},{"issue":"Pt B","key":"2022011806195922400_CIT0018","first-page":"1","article-title":"Biological agents. Volume 100 B. A review of human carcinogens","volume":"100 B","author":"Humans","year":"2012","journal-title":"IARC Monogr Eval Carcinog Risks Hum."},{"issue":"12","key":"2022011806195922400_CIT0019","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jama.1968.03140380059014","article-title":"Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-Up Study","volume":"205","author":"Saenger","year":"1968","journal-title":"JAMA."},{"issue":"6","key":"2022011806195922400_CIT0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jcem-38-6-976","article-title":"Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study","volume":"38","author":"Dobyns","year":"1974","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022011806195922400_CIT0021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/oxfordjournals.aje.a113296","article-title":"Mortality in women treated for hyperthyroidism","volume":"115","author":"Hoffman","year":"1982","journal-title":"Am J Epidemiol."},{"issue":"3","key":"2022011806195922400_CIT0022","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/ije\/11.3.218","article-title":"Cancer incidence following treatment of hyperthyroidism","volume":"11","author":"Hoffman","year":"1982","journal-title":"Int J Epidemiol."},{"issue":"1","key":"2022011806195922400_CIT0023","first-page":"63","article-title":"Breast cancer following iodine-131 therapy for hyperthyroidism","volume":"70","author":"Hoffman","year":"1983","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"2022011806195922400_CIT0024","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/oxfordjournals.aje.a114900","article-title":"Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women","volume":"127","author":"Goldman","year":"1988","journal-title":"Am J Epidemiol."},{"issue":"8","key":"2022011806195922400_CIT0025","first-page":"2283","article-title":"Cancer mortality in women with thyroid disease","volume":"50","author":"Goldman","year":"1990","journal-title":"Cancer Res."},{"issue":"7","key":"2022011806195922400_CIT0026","doi-asserted-by":"crossref","first-page":"e209660","DOI":"10.1001\/jamanetworkopen.2020.9660","article-title":"Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism","volume":"3","author":"Kitahara","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2022011806195922400_CIT0027","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/thy.2019.0205","article-title":"Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study","volume":"30","author":"Gronich","year":"2020","journal-title":"Thyroid."},{"issue":"10","key":"2022011806195922400_CIT0028","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1210\/jc.2015-1874","article-title":"Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism","volume":"100","author":"Ry\u00f6di","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022011806195922400_CIT0029","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.22635","article-title":"Increased cancer incidence after radioiodine treatment for hyperthyroidism","volume":"109","author":"Metso","year":"2007","journal-title":"Cancer."},{"issue":"9170","key":"2022011806195922400_CIT0030","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(98)12295-X","article-title":"Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study","volume":"353","author":"Franklyn","year":"1999","journal-title":"Lancet."},{"issue":"6","key":"2022011806195922400_CIT0031","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ijc.2910500611","article-title":"Cancer mortality after iodine-131 therapy for hyperthyroidism","volume":"50","author":"Hall","year":"1992","journal-title":"Int J Cancer."},{"issue":"15","key":"2022011806195922400_CIT0032","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/83.15.1072","article-title":"Cancer risk after iodine-131 therapy for hyperthyroidism","volume":"83","author":"Holm","year":"1991","journal-title":"J Natl Cancer Inst."},{"issue":"17","key":"2022011806195922400_CIT0033","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by Indication in Clinical Research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA."},{"issue":"12","key":"2022011806195922400_CIT0034","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jamainternmed.2019.5123","article-title":"Safety of the use of radioactive iodine in patients with hyperthyroidism-reply","volume":"179","author":"Kitahara","year":"2019","journal-title":"JAMA Intern Med."},{"issue":"13","key":"2022011806195922400_CIT0035","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid cancers after bone marrow transplantation","volume":"336","author":"Curtis","year":"1997","journal-title":"N Engl J Med."},{"issue":"11","key":"2022011806195922400_CIT0036","first-page":"3563","article-title":"Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France","volume":"82","author":"Pacini","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022011806195922400_CIT0037","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1667\/RR14160.1","article-title":"Organ dose estimates for hyperthyroid patients treated with (131)I: an update of the thyrotoxicosis follow-up study","volume":"184","author":"Melo","year":"2015","journal-title":"Radiat Res."},{"issue":"11","key":"2022011806195922400_CIT0038","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2967\/jnumed.119.234849","article-title":"Radioactive iodine treatment and cancer mortality in hyperthyroid patients: questioning standard clinical practice requires indisputable scientific data","volume":"60","author":"Chen","year":"2019","journal-title":"J Nucl Med."},{"issue":"12","key":"2022011806195922400_CIT0039","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1001\/jamainternmed.2019.5120","article-title":"Safety of the use of radioactive iodine in patients with hyperthyroidism","volume":"179","author":"Grady","year":"2019","journal-title":"JAMA Intern Med."},{"issue":"11","key":"2022011806195922400_CIT0040","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2967\/jnumed.119.235929","article-title":"There is no association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism","volume":"60","author":"Greenspan","year":"2019","journal-title":"J Nucl Med."},{"issue":"12","key":"2022011806195922400_CIT0041","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jamainternmed.2019.5117","article-title":"Safety of the use of radioactive iodine in patients with hyperthyroidism","volume":"179","author":"Peacock","year":"2019","journal-title":"JAMA Intern Med."},{"issue":"12","key":"2022011806195922400_CIT0042","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00259-019-04470-w","article-title":"Letter to the editor: Use of radioactive iodine treatment in patients with hyperthyroidism? A case for shared decision making","volume":"46","author":"Struja","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"10","key":"2022011806195922400_CIT0043","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/RLU.0000000000002792","article-title":"Spotlight on the association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism is keeping the highest risk from antithyroid drugs in the blind spot","volume":"44","author":"Tulchinsky","year":"2019","journal-title":"Clin Nucl Med."},{"issue":"12","key":"2022011806195922400_CIT0044","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1007\/s00259-019-04522-1","article-title":"Regarding the manuscript entitled \u201cAssociation of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism\u201d","volume":"46","author":"Zhang","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"2022011806195922400_CIT0045","doi-asserted-by":"crossref","first-page":"dgz305","DOI":"10.1210\/clinem\/dgz305","article-title":"Association of radioactive iodine treatment of hyperthyroidism with cancer mortality: an unjustified warning?","volume":"105","author":"Hindie","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022011806195922400_CIT0046","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/cen.14136","article-title":"Joint statement from the Society for Endocrinology and the British Thyroid Association regarding \u2018Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism\u2019","volume":"92","author":"Taylor","year":"2020","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2022011806195922400_CIT0047","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00259-019-04580-5","article-title":"Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies","volume":"47","author":"Verburg","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2022011806195922400_CIT0048","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/er.2009-0007","article-title":"Molecular aspects of thyroid hormone actions","volume":"31","author":"Cheng","year":"2010","journal-title":"Endocr Rev."},{"issue":"2","key":"2022011806195922400_CIT0049","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1158\/1055-9965.EPI-08-0911","article-title":"Thyroid function and cancer risk: a prospective population study","volume":"18","author":"Hellevik","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"12","key":"2022011806195922400_CIT0050","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1210\/jc.2016-2104","article-title":"Thyroid function and cancer risk: the Rotterdam study","volume":"101","author":"Khan","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022011806195922400_CIT0051","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12916-020-01690-y","article-title":"Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors","volume":"18","author":"Yang","year":"2020","journal-title":"BMC Med."},{"issue":"2","key":"2022011806195922400_CIT0052","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2010.0090","article-title":"Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners","volume":"21","author":"Greenlee","year":"2011","journal-title":"Thyroid."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab700\/40533749\/dgab700.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/2\/e448\/42224332\/dgab700.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/2\/e448\/42224332\/dgab700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T06:21:02Z","timestamp":1642486862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/2\/e448\/6374549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,9,23]]},"published-print":{"date-parts":[[2022,1,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab700","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,9,23]]}}}